Advanced Search Results

1704 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CTSL and PPP1CC cathepsin L protein phosphatase 1, catalytic subunit, gamma isozyme
  • Collagen formation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Trafficking and processing of endosomal TLR
  • Toll-Like Receptors Cascades
  • MHC class II antigen presentation
  • Endosomal/Vacuolar pathway
  • Class I MHC mediated antigen processing & presentation
  • Antigen processing-Cross presentation
  • Adaptive Immune System
  • Innate Immune System
  • Loss of Function of TGFBR2 in Cancer
  • Mitotic Prometaphase
  • Metabolism of lipids and lipoproteins
  • Separation of Sister Chromatids
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • Mitotic Anaphase
  • TGFBR1 LBD Mutants in Cancer
  • M Phase
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Lipid digestion, mobilization, and transport
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Resolution of Sister Chromatid Cohesion
  • Mitotic Metaphase and Anaphase
  • SMAD4 MH2 Domain Mutants in Cancer
  • 9,10-Deepithio-9,10-Didehydroacanthifolicin
  • Calyculin A
  • (2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID
  • Motuporin
EGFR and EPS15 epidermal growth factor receptor epidermal growth factor receptor pathway substrate 15
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by EGFR
  • EGFR downregulation
  • Signaling by EGFR in Cancer
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFRvIII in Cancer
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and STAM2 epidermal growth factor receptor signal transducing adaptor molecule (SH3 domain and ITAM motif) 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by EGFR
  • EGFR downregulation
  • Endosomal Sorting Complex Required For Transport (ESCRT)
  • Signaling by EGFR in Cancer
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFRvIII in Cancer
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and NUMB epidermal growth factor receptor numb homolog (Drosophila)
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Hedgehog 'off' state
  • Axon guidance
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • L1CAM interactions
  • Recycling pathway of L1
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Hedgehog 'on' state
  • Signaling by NOTCH1
  • Signaling by Hedgehog
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Degradation of GLI1 by the proteasome
  • Signaling by NOTCH1 in Cancer
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and HGS epidermal growth factor receptor hepatocyte growth factor-regulated tyrosine kinase substrate
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by EGFR
  • EGFR downregulation
  • Endosomal Sorting Complex Required For Transport (ESCRT)
  • Signaling by EGFR in Cancer
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFRvIII in Cancer
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
ERBB2 and HDAC6 erb-b2 receptor tyrosine kinase 2 histone deacetylase 6
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • HSF1 activation
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Organelle biogenesis and maintenance
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Assembly of the primary cilium
  • Cellular response to heat stress
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
MTOR and TERT mechanistic target of rapamycin (serine/threonine kinase) telomerase reverse transcriptase
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • mTOR signalling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • PKB-mediated events
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • S6K1-mediated signalling
  • mTORC1-mediated signalling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Costimulation by the CD28 family
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • mTOR signalling
  • S6K1-mediated signalling
  • mTORC1-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • HSF1-dependent transactivation
  • IRS-related events triggered by IGF1R
  • PI3K events in ERBB2 signaling
  • Release of eIF4E
  • VEGFR2 mediated vascular permeability
  • Downstream signaling of activated FGFR
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Cellular response to heat stress
  • Release of eIF4E
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PKB-mediated events
  • PI3K Cascade
  • Telomere Maintenance
  • Chromosome Maintenance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • Extension of Telomeres
  • Telomere Extension By Telomerase
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
FYN and PRKCZ FYN proto-oncogene, Src family tyrosine kinase protein kinase C, zeta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Host Interactions of HIV factors
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by VEGF
  • Downstream signal transduction
  • Sema3A PAK dependent Axon repulsion
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Platelet Adhesion to exposed collagen
  • Axon guidance
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • CTLA4 inhibitory signaling
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • PECAM1 interactions
  • CD28 dependent Vav1 pathway
  • Signaling by FGFR
  • Cell surface interactions at the vascular wall
  • GPVI-mediated activation cascade
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • SMAD4 MH2 Domain Mutants in Cancer
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
XRCC6 and SMAD7 X-ray repair complementing defective repair in Chinese hamster cells 6 SMAD family member 7
  • Cytosolic sensors of pathogen-associated DNA
  • HIV Infection
  • Processing of DNA ends prior to end rejoining
  • Integration of provirus
  • Early Phase of HIV Life Cycle
  • HIV Life Cycle
  • Nonhomologous End-joining (NHEJ)
  • STING mediated induction of host immune responses
  • Double-Strand Break Repair
  • IRF3-mediated induction of type I IFN
  • 2-LTR circle formation
  • Innate Immune System
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Signaling by BMP
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
GSK3A and PRKCZ glycogen synthase kinase 3 alpha protein kinase C, zeta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • XBP1(S) activates chaperone genes
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • IRE1alpha activates chaperones
  • PI3K/AKT activation
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Unfolded Protein Response (UPR)
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • SMAD4 MH2 Domain Mutants in Cancer
GSK3B and PRKCZ glycogen synthase kinase 3 beta protein kinase C, zeta
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • SMAD4 MH2 Domain Mutants in Cancer
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
NR4A1 and PPM1A nuclear receptor subfamily 4, group A, member 1 protein phosphatase, Mg2+/Mn2+ dependent, 1A
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Nuclear Receptor transcription pathway
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Generic Transcription Pathway
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Loss of Function of TGFBR2 in Cancer
  • IRS-mediated signalling
  • mTOR signalling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • mTOR signalling
  • TGFBR1 LBD Mutants in Cancer
  • IGF1R signaling cascade
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • IRS-related events triggered by IGF1R
  • Generic Transcription Pathway
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • PKB-mediated events
  • PI3K Cascade
  • Signaling by Insulin receptor
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • Insulin receptor signalling cascade
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Regulation of AMPK activity via LKB1
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • IRS-related events
  • Loss of Function of TGFBR1 in Cancer
  • IRS-mediated signalling
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PKB-mediated events
  • PI3K Cascade
  • SMAD4 MH2 Domain Mutants in Cancer
NR4A1 and NCOR2 nuclear receptor subfamily 4, group A, member 1 nuclear receptor corepressor 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Nuclear Receptor transcription pathway
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Generic Transcription Pathway
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Chromatin organization
  • HDACs deacetylate histones
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Chromatin modifying enzymes
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
IKBKB and TGFBR1 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta transforming growth factor, beta receptor 1
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • RIP-mediated NFkB activation via ZBP1
  • IRAK1 recruits IKK complex
  • Downstream signaling events of B Cell Receptor (BCR)
  • Toll Like Receptor TLR1:TLR2 Cascade
  • FCERI mediated NF-kB activation
  • Toll Like Receptor 5 (TLR5) Cascade
  • NOD1/2 Signaling Pathway
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • IRAK1 recruits IKK complex
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • TCR signaling
  • Signaling by Interleukins
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Innate Immune System
  • Signalling by NGF
  • IKK complex recruitment mediated by RIP1
  • Cytosolic sensors of pathogen-associated DNA
  • p75 NTR receptor-mediated signalling
  • Cytokine Signaling in Immune system
  • MyD88-independent cascade
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Activation of NF-kappaB in B cells
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Loss of Function of TGFBR2 in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Mesalazine
  • Sulfasalazine
  • Auranofin
  • Arsenic trioxide
IKBKB and PRKCZ inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta protein kinase C, zeta
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • RIP-mediated NFkB activation via ZBP1
  • IRAK1 recruits IKK complex
  • Downstream signaling events of B Cell Receptor (BCR)
  • Toll Like Receptor TLR1:TLR2 Cascade
  • FCERI mediated NF-kB activation
  • Toll Like Receptor 5 (TLR5) Cascade
  • NOD1/2 Signaling Pathway
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • IRAK1 recruits IKK complex
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • TCR signaling
  • Signaling by Interleukins
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Innate Immune System
  • Signalling by NGF
  • IKK complex recruitment mediated by RIP1
  • Cytosolic sensors of pathogen-associated DNA
  • p75 NTR receptor-mediated signalling
  • Cytokine Signaling in Immune system
  • MyD88-independent cascade
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Activation of NF-kappaB in B cells
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • SMAD4 MH2 Domain Mutants in Cancer
  • Mesalazine
  • Sulfasalazine
  • Auranofin
  • Arsenic trioxide
IRS1 and PRKCZ insulin receptor substrate 1 protein kinase C, zeta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • SOS-mediated signalling
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Adaptive Immune System
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • IRS-related events triggered by IGF1R
  • IRS activation
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PI3K Cascade
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • SMAD4 MH2 Domain Mutants in Cancer
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
ITK and TGFBR1 IL2-inducible T-cell kinase transforming growth factor, beta receptor 1
  • TCR signaling
  • Generation of second messenger molecules
  • Fc epsilon receptor (FCERI) signaling
  • FCERI mediated Ca+2 mobilization
  • Innate Immune System
  • Adaptive Immune System
  • Loss of Function of TGFBR2 in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Staurosporine
  • Pazopanib
JAK1 and PRKCZ Janus kinase 1 protein kinase C, zeta
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Interferon gamma signaling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Interleukin receptor SHC signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • Interleukin-7 signaling
  • SOS-mediated signalling
  • SHC-mediated signalling
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • ERK1 activation
  • GPCR downstream signaling
  • Signaling by VEGF
  • Toll Like Receptor 3 (TLR3) Cascade
  • Signalling to RAS
  • Downstream signal transduction
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Axon guidance
  • IRS-mediated signalling
  • Interleukin-6 signaling
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • Insulin receptor signalling cascade
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Signaling by FGFR
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • Regulation of IFNA signaling
  • G-protein beta:gamma signalling
  • GRB2 events in EGFR signaling
  • SHC-related events triggered by IGF1R
  • Signaling by ERBB4
  • Antiviral mechanism by IFN-stimulated genes
  • Signaling by ERBB2
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • G beta:gamma signalling through PI3Kgamma
  • Downstream signaling of activated FGFR
  • Interferon alpha/beta signaling
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • ERK2 activation
  • Regulation of IFNG signaling
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • SMAD4 MH2 Domain Mutants in Cancer
JAK2 and PPP1CC Janus kinase 2 protein phosphatase 1, catalytic subunit, gamma isozyme
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Interferon gamma signaling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Interleukin receptor SHC signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Prolactin receptor signaling
  • SHC-mediated signalling
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • ERK1 activation
  • GPCR downstream signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Signalling to RAS
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Axon guidance
  • IRS-mediated signalling
  • Interleukin-6 signaling
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • Insulin receptor signalling cascade
  • Interferon Signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • RMTs methylate histone arginines
  • Signaling by FGFR
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Nuclear signaling by ERBB4
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • G-protein beta:gamma signalling
  • Chromatin organization
  • GRB2 events in EGFR signaling
  • SHC-related events triggered by IGF1R
  • Factors involved in megakaryocyte development and platelet production
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Chromatin modifying enzymes
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Growth hormone receptor signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • G beta:gamma signalling through PI3Kgamma
  • Downstream signaling of activated FGFR
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • ERK2 activation
  • Regulation of IFNG signaling
  • Loss of Function of TGFBR2 in Cancer
  • Mitotic Prometaphase
  • Metabolism of lipids and lipoproteins
  • Separation of Sister Chromatids
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • Mitotic Anaphase
  • TGFBR1 LBD Mutants in Cancer
  • M Phase
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Lipid digestion, mobilization, and transport
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Resolution of Sister Chromatid Cohesion
  • Mitotic Metaphase and Anaphase
  • SMAD4 MH2 Domain Mutants in Cancer
  • 9,10-Deepithio-9,10-Didehydroacanthifolicin
  • Calyculin A
  • (2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID
  • Motuporin
LYN and PPP1R15A LYN proto-oncogene, Src family tyrosine kinase protein phosphatase 1, regulatory subunit 15A
  • Signaling by the B Cell Receptor (BCR)
  • Platelet Adhesion to exposed collagen
  • Axon guidance
  • Costimulation by the CD28 family
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • Regulation of KIT signaling
  • FCERI mediated NF-kB activation
  • EPH-ephrin mediated repulsion of cells
  • Regulation of signaling by CBL
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • CD28 co-stimulation
  • CTLA4 inhibitory signaling
  • Cytokine Signaling in Immune system
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Cell surface interactions at the vascular wall
  • PECAM1 interactions
  • Signaling by Interleukins
  • Fc epsilon receptor (FCERI) signaling
  • GPVI-mediated activation cascade
  • FCERI mediated Ca+2 mobilization
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Growth hormone receptor signaling
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
Page 17 out of 86 pages